Ultragenyx Sells Part of Future North American Royalties on Crysvita (burosumab) for $400 M

 Bolsters balance sheet with non-dilutive capital at an attractive cost

Beginning in January 2028 OMERS will receive an additional 25% of the North American Crysvita® royalty interest capped at 1.55 times the purchase price

Proceeds to fund four expected launches, setting the company up for the next stage of growth

https://finviz.com/news/217453/ultragenyx-announces-sale-of-a-portion-of-future-north-american-royalties-on-crysvita-burosumab-for-400-million-to-omers-life-sciences